One of the hallmarks of cystic fibrosis is the propensity of patients to develop lung infections with Pseudomonas aeruginosa, which eventually compromises lung function. New data suggest loss of CFTR impairs lipoxin production, thus preventing resolution of lung inflammation and creating an environment susceptible to further infection.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Riordan, J.R. et al. Science 245, 1066–1073 (1989).
Gibson, R.L., Burns, J.L. & Ramsey, B.W. Am. J. Respir. Crit. Care Med. 168, 918–951 (2003).
Verkman, A.S., Song, Y. & Thiagarajah, J.R. Am. J. Physiol. Cell Physiol. 284, C2–15 (2003).
Karp, C.L. Nat. Immunol. 5, 388–392 (2004).
Serhan, C.N. Prostaglandins Other Lipid Mediat. 68–69, 433–455 (2002).
Nagase, T. et al. Biochem. Biophys. Res. Commun. 168, 485–489 (1990).
Serhan, C.N. et al. J. Exp. Med. 196, 1025–1037 (2002).
Samuelsson, B., Dahlen, S.E., Lindgren, J.A., Rouzer, C.A. & Serhan, C.N. Science 237, 1171–1176 (1987).
Shimizu, T. & Wolfe, L.S. J. Neurochem. 55, 1–15 (1990).
Nagase, T. et al. Nat. Immunol. 1, 42–46 (2000).
Nagase, T. et al. Nat. Med. 8, 480–484 (2002).
Konstan, M.W., Byard, P.J., Hoppel, C.L. & Davis, P.B. N. Engl. J. Med. 332, 848–854 (1995).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Takai, D., Nagase, T. & Shimizu, T. New therapeutic key for cystic fibrosis: a role for lipoxins. Nat Immunol 5, 357–358 (2004). https://doi.org/10.1038/ni0404-357
Issue Date:
DOI: https://doi.org/10.1038/ni0404-357
This article is cited by
-
Anti-inflammatory Therapies for Cystic Fibrosis-Related Lung Disease
Clinical Reviews in Allergy & Immunology (2008)
